

June 6, 2024

Jefferies Healthcare Conference



Disclaimer

Forward-Looking Statements

This presentation and the accompanying oral commentary (this "presentation") contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "would", "would", "understand" and similar words are intended to identify forward looking statements. These forwardlooking statements include but are not limited to, statements regarding our future operating results and financial position, our business strategy and plans, our objectives for future operations, macroeconomic trends, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, our future share capitalization and any exercise, exchange or other settlement of our outstanding warrants and other securities. There are a significant number of factors that could cause actual results to differ materially from statements made in this presentation, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, especially related to matters affecting Russia, the relationship between the United States and China and conflict in the Middle East; risks related to the public's perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology disruption or security; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures and investments, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; risks associated with our limited history of operating as an independent company; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the Securities and Exchange Commission (the "SEC") from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Basis of Presentation

As a result of the business combination (the "Business Combination") between Mirion Technologies (TopCo), Ltd. and GS Acquisition Holdings Corp II ("GSAH"), the Company's financial statement presentation distinguishes Mirion TopCo as the "Predecessor" until the closing date of the Business Combination, October 20, 2021 (the "Closing Date"). Mirion Technologies, Inc. ("Mirion" or the "Company"), which includes the combination of Mirion TopCo and GSAH subsequent to the Business Combination, is the "Successor" for periods starting from the Closing Date. As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor period are presented on a full step-up basis as a result of the Business Combination, and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis due to the Business Combination.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including Adjusted Revenue, Organic Revenue, Adjusted Gross Profit, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow, Adjusted Net Income, Organic Order Growth and Net Leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion's control or cannot be reasonably predicted. Accordingly, a reconciliation for our guidance for Organic Revenue Growth, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow and Net Leverage is not available wit

Industry and Market Data

In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from thirdparty sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness.

MIRION MISSION

To harness our unrivaled knowledge of ionizing radiation for the greater good of humanity

With safety at the core of our solutions, Mirion:

- Enables safer production of nuclear power, supporting global energy production and carbon neutrality
- Provides a safer working environment for medical professionals
- Assists patients to obtain the life-saving treatments they need
- Helps protect heroes on the front-lines



Strong Leadership Founded on Innovation & Scale

MIRION CREATED 2005	130+ PATENTS ¹	#1 POSITION IN 16 OF 19 product categories	700+ UNIQUE PRODUCTS
OPERATIONS SPAN ACROSS 12 COUNTRIES	20-50 YEAR CUSTOMER RELATIONSHIPS ²	350+ ENGINEERS & PHYSICISTS	2,800 EMPLOYEES

¹All data as of June 2024, unless otherwise noted: 0+ U.S. patents, 60+ foreign utility patents ² Includes relationships from predecessor organizations

Investment Thesis



leader in ionizing radiation safety supported by unmatched scale



High visibility into long term recurring revenue growth



Delivers safety and **compulsory products** to **blue chip customer** profile at **attractive margins**



Resilient business model through varying economic cycles



Committed to driving success through operational excellence

_ _	

Diversified product portfolio with vertical flexibility



Strong competitive moat strengthened by technology-focused innovation



Disciplined capital allocation focused on generating shareholder value

Medical Segment Overview

CY23 Medical Revenue¹ Nuclear Medicine 19% \$285 56% Radiation Therapy QA

RADIATION THERAPY QUALITY ASSURANCE

Premium Category Leadership

Leading Hardware & Software Solutions for Patient & Machine QA

100% of the **Top 100 Cancer Centers** in the US

> ~80% of Cancer Centers World-Wide

6

NUCLEAR MEDICINE

A Global Leader in Chosen Categories

Dose Calibration

Thyroid Uptake Systems

Well Counters

Lung Ventilation Systems

End-to-End Workflow Software

OCCUPATIONAL DOSIMETRY

Technology & Innovation Focused

#2 Player in the US Market With >3x Revenue of The Next Nearest Competitor


Growth Opportunity in European Market

Leading the **Digital Revolution** in Occupational Dosimetry

Source: Mirion estimates, Global Consulting Firm; All data as of June 2024 unless otherwise noted ¹CY23 Revenue of \$285M and end market published in earnings presentation on February 14, 2024

Technologies Segment Overview

CY23 Technologies Revenue¹





Q1 Earnings Recap

- Customer engagement strong across all end markets; Adjusted Order Decline of ~(1)% compared to Q1 2023
- Consolidated Q1 Organic Revenue Growth of +5.5%; Medical +0.6% and Technologies +8.4%
- Adjusted EBITDA of \$39.5M in Q1 2024, Adjusted EBITDA margin of 20.5% an expansion of 40-basis points from Q1 2023
- Adjusted Free Cash Flow of \$(4.5)M in Q1 2024; net leverage¹ at 3.1x
- 2024 guidance²: organic growth of 4% 6%, Adjusted EBITDA of \$193M - \$203M, Adjusted Free Cash Flow of \$65M - \$85M

1) Net leverage defined as total net debt divided by M&A Adjusted EBITDA.

2) Guidance provided on May 1, 2024 and has not been updated or refreshed since that date.

Appendix

10

Illustrative Share Count Details After Warrant Conversions¹

Share Description	Outstanding Securities ²	Notes
Outstanding Shares of Class A Common Stock (as of 3/31/2024)	199,985,333	 Outstanding shares as of close of trading on the New York Stock Exchange (NYSE) March 31, 2024
Shares Issued in Public Warrant Conversion	3,978,418	 On May 23, 2024, Mirion announced the completion of the redemption of its outstanding public warrants. Of the 18,749,779 Public Warrants that were outstanding as of March 31, 2024, 2,131 were exercised for cash at an exercise price of \$11.50 per Common Share in exchange for an aggregate of 2,131 Common Shares and 18,074,285 were exercised on a cashless basis in exchange for an aggregate of 3,976,287 Common Shares, in each case in accordance with the terms of the Warrant Agreement, representing approximately 96.4% of the outstanding Public Warrants in the aggregate. A total of 673,363 Public Warrants remained unexercised as of the Redemption Date, and the Company redeemed those Public Warrants for an aggregate redemption price of \$67,336.30.
Shares Issued in Private Warrant Conversion	1,768,000	 On June 4, 2024, Mirion entered into a warrant exchange agreement with GS Sponsor II LLC. Pursuant to the Warrant Exchange Agreement, the Company agreed to issue an aggregate of 1,768,000 shares of the Company's Class A common stock, par value \$0.0001 per share, to GS Sponsor II LLC upon the exchange of 8,500,000 warrants to purchase shares of the Company's Class A common stock held by GS Sponsor II LLC.
Illustrative Class A Shares Outstanding	205,731,751	 Calculated as the sum of the outstanding shares of common stock as of 3/31/2024, the shares issued in public warrant conversion and the shares issued in private warrant conversion.
Shares of Class B Common Stock – Mirion Management ³ (as of 3/31/2024)	7,326,423	 Shares of Class B common stock are owned by certain current and former members of Mirion's management team and are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co, Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one-basis or cash based on a trailing stock price average.
Shares of Class A Common Stock – Founder Shares (as of 3/31/2024)	18,750,000	 Founders shares vest in three equal tranches, based on the VWAP of our Class A common stock being greater than or equal to \$12.00, \$14.00 and \$16.00 per share for any 20 trading days in any 30 consecutive trading day period, and such shares will be forfeited to us for no consideration if they fail to vest by October 20, 2026.
Illustrative Total Shares Outstanding	231,808,174	
Outstanding Equity Awards ⁴ (as of 3/31/2024)	3,403,506	 Mirion had 2.2 million shares of restricted stock units and 1.2 million shares of performance stock units outstanding as of March 31, 2024. Additionally, Mirion had reserved an additional 34.3 million shares of Class A common stock for future equity awards issuance under its 2021 Omnibus Incentive Plan (subject to annual automatic increases) as of March 31, 2024.
Total Illustrative Fully Diluted Shares	235,211,680	

- 1) All data on this slide is as of March 31, 2024, unless otherwise noted. All share numbers and dollar amounts are subject to adjustment for stock splits or other similar events.
- 2) This slide illustrates Mirion's outstanding and fully diluted shares based on certain assumptions set forth in the "Notes' column and is designed to be illustrative and provide investors with additional information only. Different assumptions will yield different results, and the actual number of our fully diluted shares in the future may differ significantly from those based on these assumptions. As a result, you should not rely on these forward-looking statements as predictions of future events. The information provided is not presented in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share (ASC 260) and does not represent a computation of weighted average shares nor are the numbers appropriate for calculating Basic or Diluted EPS under ASC 260.
- The slide illustrates the assumption that all of the paired interests will be redeemed and exchanged for shares of Class A common stock.
- 4) The number of reserved shares are subject to automatic increases on the first day of each year in an amount equal to the lesser of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately preceding year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by Mirion Compensation Committee in its discretion.



Significant Leverage to Key End Market Trends

TECHNOLOGIES



MEDICAL

2024 JEFFERIES HEALTHCARE CONFERENCE

CY23 Mirion Revenue¹


\$801

Medical

Technologies

Medical Value-Added Solutions

Diversified product portfolio in resilient end markets. Supported by aging population and growing global middle class.



2024 JEFFERIES HEALTHCARE CONFERENCE

Technologies Value-Added Solutions

Technology leadership, rigorous regulatory requirements, and demanding design all contribute to high barriers of entry.



Technologies \$801 Medical

CY23 Mirion Revenue¹

Radiation Measurement & Health Physics Instrumentation

Search & Radiological Security Systems

Radiation Monitoring Systems

Radiation Instrumentation and Controls


Nuclear Power: An Essential Source of Green Energy

Our View: The world cannot achieve carbon neutrality goals without wide proliferation of nuclear power **Our Role:** Mirion services all stages of a plant's lifecycle and is technology-agnostic across nuclear OEMs; solutions are key to the safety of personnel and materials from radiation and ensuring effective operation

Positive Outlook | Nuclear market conditions strongest in decades

- Global push for carbon neutrality to be a key growth factor going forward in medium- and longer-term horizon
- Desire for energy independence, re-shoring trends
- Robust government support for reliable and diverse supply of energy sources, enabling nuclear re-investment and new builds
- Higher gas prices supporting better economics for existing nuclear fleet and higher capacity requirements

Illustrative Revenue Opportunity For Mirion Across Traditional NPP Cycle *Typical revenue profile assuming 60-year operational life*




SMRs: The Future of Nuclear Power

- Game-changing development in the nuclear space to replace coal plants
- Growing opportunity for Mirion
- Establishing relationships across population of SMR designers
- Mirion's solutions will remain OEM and design agnostic

Record of Driving Value Through M&A

Select Transactions Completed Since 2016



TECHNOLOGIES – MEDICAL

REVENUE AT TIME OF ACQUISITION

Mirion's success reflects effective M&A over 15+ years

Active M&A function with talent and capabilities to pursue large transactions

~\$200-\$250M Revenue Acquisition of Canberra

Institutional knowledge for identifying, acquiring, and integrating targets

~\$400M Sales Generated via M&A Since 2016

Proven and consistent track record delivering on synergy capture

Broad Product Portfolio Addresses Attractive End Markets

MARKET LEADERSHIP

CATEGORY	BU	END MARKET(S)
Radiation Monitoring Systems	Technologies	8
Reactor Instrumentation & Controls	Technologies	898
Imaging Systems for Extreme Environments	Technologies	
NDA, Waste Measurement & Criticality Systems	Technologies	<u></u>
Physical & Cyber Security Systems	Technologies	26
Gamma Spectroscopy Detector Systems	Technologies	x 🕺 🔮 🕸
Alpha Spectroscopy Instruments	Technologies	₹ <u>₹</u>
Alpha/Beta Counting Instruments	Technologies	8 De la companya de l
Research, Education & Industrial Solutions	Technologies	₹¢-
Contamination & Clearance Monitors	Technologies	2 kg
Portable Radiation Measurement	Technologies	AB C
Military Radiation Measurement Instruments	Technologies	Ø
Active Dosimetry & Telemetry Systems	Technologies Medical	🗟 💑 🌽 🔯
Cancer Diagnostics & Therapeutics QA	Medical	
Nuclear Medicine	Medical	[201] [201]
Occupational Dosimetry Services	Medical	

FRAGMENTED

CATEGORY	BU	END MARKET
Medical Imaging	Medical	[20]
Security & Search Systems	Technologies	
Nuclear Power	È	Labs & Research
Defense & Diversified	@ 000000000000000000000000000000000000	Occupational Dosimetry
😥 RT QA		3] Nuclear Medicine

MIRION

ESG is Integrated into Mirion's Mission

Mirion's ESG Policies, Programs & Initiatives serve to support our mission of harnessing our unrivaled knowledge of ionizing radiation for the greater good of humanity.



Committed to Responsible and Sustainable Operations

We recognize ESG as a fundamental piece to our future success



We are in the early stages of our ESG journey as a public company. We are committed to advancing our ESG initiatives and will rely on the input from global stakeholders and regulatory agencies to guide future priorities.

RECENT ACCOMPLISHMENTS:

Integration of ESG best practices into our Corporate Governance:

- ESG oversight including climate related risks and cybersecurity
- Requiring skills and expertise for our Board to include ESG and cybersecurity

Developed formal policies and programs including:

- ✓ Supplier Code of Conduct
- ✓ Whistleblower

Initiated conversations and reports with ESG rating agencies

CURRENT EFFORTS:

- Working to publish our inaugural Sustainability Report with SASBaligned disclosure
- Conducting an initial energy audit to create a roadmap for future scope 1 and 2 emissions inventory

FUTURE GOALS:

- Establish concrete ESG targets to measure ESG progression
- Showcase improvement in ESG ratings
- Enhance public ESG disclosures



Medical

								Suc	cessor								
Q1	2024	Q4	2023	Q3	2023	Q2	2023	Q1	2023	Q4 2	022	Q3	2022	Q2	2022	Q1	2022
\$	66.8	\$	81.3	\$	68.8	\$	68.0	\$	66.4	\$	76.1	\$	68.7	\$	66.8	\$	60.1
	0.6 %		6.8 %		0.1 %		1.8 %		10.5 %		25.4 %		23.3 %		19.6 %		7.7 %
	0.6 %		9.6 %		5.2 %		6.9 %		10.8 %		23.6 %		20.7 %		15.1 %		0.7 %
	(0.1)%		(3.2)%		(5.8)%		(5.2)%		— %		2.8 %		4.4 %		5.8 %		7.7 %
	0.1 %		0.4 %		0.7 %		0.1 %		(0.3)%		(1.0)%		(1.8)%		(1.3)%		(0.6)%
\$	1.4	\$	11.4	\$	4.0	\$	(3.1)	\$	0.7	\$	(86.6)	\$	(3.3)	\$	(2.2)	\$	(6.7)
	13.7		13.7		13.5		13.7		13.9		14.7		15.3		17.0		17.3
	3.6		4.1		4.1		3.6		3.9		3.7		3.5		3.5		2.6
	1.2		1.2		1.2		1.2		1.2		1.2		1.2		1.2		1.2
	0.2		0.2		0.2		0.2		0.1		0.2		0.1		0.2		0.1
	_		_		_		_		_		_		_		_		0.9
	_		_		_		_		_		87.3		_		_		_
	0.4		0.7		0.6		6.7		0.6		5.4		3.8		2.1		3.2
	_		_		(0.1)		_		_		(0.4)		(0.1)		0.4		_
\$	20.5	\$	31.3	\$	23.5	\$	22.3	\$	20.4	\$	25.4	\$	20.4	\$	22.2	\$	18.6
	2.0 %		14.0 %		5.8 %		(4.6)%		1.1 %	(1	13.8)%		(4.8)%		(3.3)%		(11.1)%
	30.7 %		38.5 %		34.2 %		32.8 %		30.7 %		33.4 %		29.7 %		33.2 %		30.9 %
	Q1 \$ \$	0.6 % 0.6 % (0.1)% 0.1 % \$ 1.4 13.7 3.6 1.2 0.2 0.2 0.4 \$ 20.5 2.0 %	\$ 66.8 \$ 0.6 % 0.6 % 0.6 % (0.1)% 0.1 % \$ 1.4 \$ 13.7 3.6 12 0.2 0.4 \$ 20.5 \$ 2.0 %	\$ 66.8 \$ 81.3 0.6 % 6.8 % 9.6 % 0.6 % 9.6 % (3.2)% 0.1 % 0.4 % \$ 1.4 \$ 11.4 13.7 13.7 3.6 4.1 1.2 1.2 0.2 0.2 0.2 0.2 0.4 0.7 0.4 0.7 0.4 0.7 0.4 0.7 0.4 0.7 0.4 0.7 0.5 \$ 31.3 2.0 % 14.0 %	\$ 66.8 \$ 81.3 \$ 0.6 % 6.8 % 9.6 % 0.6 % 0.6 % 0.1 % 0.4 % \$ 1.4 \$ 11.4 \$ 13.7 13.7 13.7 13.7 3.6 4.1 1.2 1.2 0.2 0.2 0.2 0.2 0.2 0.4 0.7	\$ 66.8 \$ 81.3 \$ 68.8 0.6 % 6.8 % 0.1 % 0.6 % 5.2 % (0.1)% (3.2)% (5.8)% 0.1 % 0.4 % 0.7 % \$ 1.4 \$ 4.0 13.7 13.7 13.5 3.6 4.1 4.1 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.2 0.2 0.4 0.7 0.6 - - - 0.4 0.7 0.6 - - - 0.4 0.7 0.6 - - (0.1) \$ 20.5 \$ 31.3 \$ 23.5 2.0 % 14.0 % 5.8 %	\$ 66.8 \$ 81.3 \$ 68.8 \$ 0.6 % 6.8 % 0.1 % 0.6 % 5.2 % 0.1 % 0.6 % 5.2 % 0.1 % <td< td=""><td>\$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 0.6 % 6.8 % 0.1 % 1.8 % 0.6 % 9.6 % 5.2 % 6.9 % (0.1)% (3.2)% (5.8)% (5.2)% 0.1 % 0.4 % 0.7 % 0.1 % \$ 1.4 \$ 11.4 \$ 4.0 \$ (3.1) 13.7 13.7 13.5 13.7 3.6 4.1 4.1 3.6 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 - - - - 0.4 0.7 0.6 6.7 - - - - 0.4 0.7 0.6 6.7 - - - - 0.4 0.7 0.6 6.7 - - - - - 0.4 0.7 5.8 % (4.6)%</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.8 \$ 68.0 \$ 0.6 % 6.8 % 0.1 % 1.8 % \$ \$ 0.6 % 9.6 % 5.2 % 6.9 % \$ \$ 0.6 % 9.6 % 5.2 % 6.9 % \$ \$ (0.1)% (3.2)% (5.8)% (5.2)% \$ 0.1 % 0.4 % 0.7 % 0.1 % \$ 13.7 13.7 13.5 13.7 \$ 3.6 4.1 4.1 3.6 \$ \$ 1.2 1.2 1.2 1.2 1.2 \$ 0.2 0.2 0.2 0.2 0.2 \$ 0.4 0.7 0.6 6.7 \$ 0.4 0.7 0.6 6.7 \$ 0.4 0.7 0.6 6.7 \$ 0.7 0.6 6.7 \$ \$</td><td>\$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % (0.1)% (3.2)% (5.8)% (5.2)% % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% \$ 1.4 \$ 11.4 \$ 4.0 \$ (3.1) \$ 0.7 13.7 13.7 13.7 13.5 13.7 13.9 3.6 4.1 4.1 3.6 3.9 1.2 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 </td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 0.1 % 0.3 % (5.8)% (5.2)% % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% 13.7 13.7 13.7 13.5 13.7 13.9 3.6 4.1 4.1 3.6 3.9 0.2 0.2 0.2 0.2 0.2 0.1 13.7 13.7 13.7 13.6 3.9</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % (0.1)% (3.2)% (5.8)% (5.2)% % 2.8 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% 7 0.1 % (0.3)% (1.0)% (1.0)% (1.0)% 7 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% 7 13.7 13.5 13.7 13.9 14.7 3.6 4.1 4.1 3.6 3.9 3.7 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 - -</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % \$ 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % \$ 0.1 % (3.2)% (5.8)% (5.2)% % 2.8 % \$ 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% \$ 1.4 \$ 11.4 \$ 4.0 \$ 0.7 \$ 0.7 \$ (86.6) \$ 13.7 13.7 13.5 13.7 13.9 14.7 3.6 4.1 4.1 3.6 3.9 3.7 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 - - - - - - - 0.2 0.2<</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 23.3 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % 20.7 % (0.1)% (3.2)% (5.8)% (5.2)% -% 2.8 % 4.4 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 13.7 13.7 13.5 13.7 13.9 14.7 15.3 1.2 1.2 1.2 1.2 1.2 1.2</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 23.3 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % 20.7 % (0.1)% (3.2)% (5.8)% (52)% % 2.8 % 4.4 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 11.4 \$ 11.4 \$ 4.0 \$ (3.1) \$ 0.7 \$ (86.6) \$ (3.3) \$ 13.7 13.7 13.5 13.7 13.9 14.7 15.3 12 1.2 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 13.7 13.7 13.5 13.7 13.9 14.7 15.3</td><td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2023 Q4 2023 Q4 2022 Q3 2022 Q2 2022 \$ 66.4 \$ 76.1 \$ Q3 2023 \$ 66.8 \$ \$ 66.8 \$ 76.1 \$ Q3 2023 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ 68.7 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 61.3 \$ 76.1 \$ \$ 66.8 \$ 61.3 \$ 76.1 \$ \$ 66.8 \$ 76.1<td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 \$ 02 2022 Q1 Q1 Q2 Q1 Q2 Q3 % 66.8 % 61.4 % % % % % % % % % %</td></td></td<>	\$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 0.6 % 6.8 % 0.1 % 1.8 % 0.6 % 9.6 % 5.2 % 6.9 % (0.1)% (3.2)% (5.8)% (5.2)% 0.1 % 0.4 % 0.7 % 0.1 % \$ 1.4 \$ 11.4 \$ 4.0 \$ (3.1) 13.7 13.7 13.5 13.7 3.6 4.1 4.1 3.6 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 - - - - 0.4 0.7 0.6 6.7 - - - - 0.4 0.7 0.6 6.7 - - - - 0.4 0.7 0.6 6.7 - - - - - 0.4 0.7 5.8 % (4.6)%	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.8 \$ 68.0 \$ 0.6 % 6.8 % 0.1 % 1.8 % \$ \$ 0.6 % 9.6 % 5.2 % 6.9 % \$ \$ 0.6 % 9.6 % 5.2 % 6.9 % \$ \$ (0.1)% (3.2)% (5.8)% (5.2)% \$ 0.1 % 0.4 % 0.7 % 0.1 % \$ 13.7 13.7 13.5 13.7 \$ 3.6 4.1 4.1 3.6 \$ \$ 1.2 1.2 1.2 1.2 1.2 \$ 0.2 0.2 0.2 0.2 0.2 \$ 0.4 0.7 0.6 6.7 \$ 0.4 0.7 0.6 6.7 \$ 0.4 0.7 0.6 6.7 \$ 0.7 0.6 6.7 \$ \$	\$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % (0.1)% (3.2)% (5.8)% (5.2)% % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% \$ 1.4 \$ 11.4 \$ 4.0 \$ (3.1) \$ 0.7 13.7 13.7 13.7 13.5 13.7 13.9 3.6 4.1 4.1 3.6 3.9 1.2 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 0.1 % 0.3 % (5.8)% (5.2)% % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% 13.7 13.7 13.7 13.5 13.7 13.9 3.6 4.1 4.1 3.6 3.9 0.2 0.2 0.2 0.2 0.2 0.1 13.7 13.7 13.7 13.6 3.9	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % (0.1)% (3.2)% (5.8)% (5.2)% % 2.8 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% 7 0.1 % (0.3)% (1.0)% (1.0)% (1.0)% 7 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% 7 13.7 13.5 13.7 13.9 14.7 3.6 4.1 4.1 3.6 3.9 3.7 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 - -	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % \$ 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % \$ 0.1 % (3.2)% (5.8)% (5.2)% % 2.8 % \$ 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% \$ 1.4 \$ 11.4 \$ 4.0 \$ 0.7 \$ 0.7 \$ (86.6) \$ 13.7 13.7 13.5 13.7 13.9 14.7 3.6 4.1 4.1 3.6 3.9 3.7 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 - - - - - - - 0.2 0.2<	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 23.3 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % 20.7 % (0.1)% (3.2)% (5.8)% (5.2)% -% 2.8 % 4.4 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 13.7 13.7 13.5 13.7 13.9 14.7 15.3 1.2 1.2 1.2 1.2 1.2 1.2	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 \$ 0.6 % 6.8 % 0.1 % 1.8 % 10.5 % 25.4 % 23.3 % 0.6 % 9.6 % 5.2 % 6.9 % 10.8 % 23.6 % 20.7 % (0.1)% (3.2)% (5.8)% (52)% % 2.8 % 4.4 % 0.1 % 0.4 % 0.7 % 0.1 % (0.3)% (1.0)% (1.8)% 11.4 \$ 11.4 \$ 4.0 \$ (3.1) \$ 0.7 \$ (86.6) \$ (3.3) \$ 13.7 13.7 13.5 13.7 13.9 14.7 15.3 12 1.2 1.2 1.2 1.2 1.2 1.2 1.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 13.7 13.7 13.5 13.7 13.9 14.7 15.3	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2023 Q4 2023 Q4 2022 Q3 2022 Q2 2022 \$ 66.4 \$ 76.1 \$ Q3 2023 \$ 66.8 \$ \$ 66.8 \$ 76.1 \$ Q3 2023 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 66.8 \$ 66.8 \$ 76.1 \$ 68.7 \$ 66.8 \$ 76.1 \$ \$ 66.8 \$ 61.3 \$ 76.1 \$ \$ 66.8 \$ 61.3 \$ 76.1 \$ \$ 66.8 \$ 76.1 <td>Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 \$ 02 2022 Q1 Q1 Q2 Q1 Q2 Q3 % 66.8 % 61.4 % % % % % % % % % %</td>	Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 \$ 66.8 \$ 81.3 \$ 68.8 \$ 68.8 \$ 68.0 \$ 66.4 \$ 76.1 \$ 68.7 \$ 02 2022 Q1 Q1 Q2 Q1 Q2 Q3 % 66.8 % 61.4 % % % % % % % % % %

Technologies

									Suc	cessor								
(\$ in millions)	Q1	2024	Q4	2023	Q3	2023	Q2	2023	Q1	2023	Q4	2022	Q3	2022	Q2	2022	Q1	2022
Revenue	\$	125.8	\$	149.1	\$	122.4	\$	129.2	\$	115.7	\$	141.8	\$	92.2	\$	109.0	\$	103.1
YoY % Growth - Total		8.7 %		5.1 %		32.8 %		18.5 %		12.2 %		17.9 %		(0.1)%		(14.7)%		(10.2)%
YoY % Growth - Organic		8.4 %		3.0 %		26.3 %		9.3 %		6.1 %		16.8 %		2.0 %		(9.0)%		(6.6)%
YoY % Growth - Acquisitions		— %		— %		2.7 %		8.2 %		9.1 %		8.2 %		6.0 %		— %		— %
YoY % Growth - FX		0.3 %		2.1 %		3.8 %		1.0 %		(3.0)%		(7.1)%		(8.1)%		(5.7)%		(3.6)%
Income (Loss) from Operations	\$	12.6	\$	22.3	\$	5.4	\$	12.8	\$	5.5	\$	(50.8)	\$	(3.3)	\$	(46.5)	\$	(2.5)
Amortization		17.8		18.1		19.2		19.5		19.7		19.6		19.9		20.5		21.5
Depreciation - core		2.1		2.4		2.2		2.2		2.2		2.3		2.1		1.9		1.9
Depreciation - Mirion Business Combination step-up		0.3		0.4		0.3		0.3		0.3		0.3		0.3		0.4		0.4
Stock compensation		0.4		0.5		0.3		0.3		0.2		0.3		0.3		0.3		0.1
Cost of revenue impact from purchase accounting		_		_		_		_		_		_		_		_		5.4
Goodwill impairment		_		_		_		_		_		69.3		_		55.2		_
Non-operating expenses		_		0.2		0.3		0.2		0.6		1.9		0.8		1.2		1.1
Other income/expense		(0.1)		0.1		_		(0.1)		_		(0.1)		0.1		_		_
Adjusted EBITDA	\$	33.1	\$	44.0	\$	27.7	\$	35.2	\$	28.5	\$	42.8	\$	20.2	\$	33.0	\$	27.9
Income from operations margin		10.0 %		15.0 %		4.4 %		9.9 %		4.8 %		(35.8)%		(3.6)%		(42.7)%		(2.4)%
Adjusted EBITDA margin		26.3 %		29.5 %		22.6 %		27.2 %		24.6 %		30.2 %		21.9 %		30.3 %		27.1 %

Corporate & Other

									Suc	cessor								
(\$ in millions)	Q1 2	2024	Q4	2023	Q3	2023	0	2 2023	Q1	2023	Q4	2022	Q3	2022	Q2	2022	Q1	2022
Revenue	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_
Income (Loss) from Operations	\$	(18.9)	\$	(20.3)	\$	(20.5)		\$ (20.3)	\$	(19.8)	\$	(24.5)	\$	(21.0)	\$	(25.9)	\$	(24.4)
Amortization		_		_		_		_		_		_		_		_		_
Depreciation - core		_		0.1		_		0.2		0.1		0.3		0.2		0.2		0.1
Depreciation - Mirion Business Combination step-up		0.1		_		0.1		0.1		0.1		_		0.1		0.1		_
Stock compensation		3.0		3.5		5.6		5.5		5.3		6.5		8.1		8.0		7.6
Goodwill impairment		_		_		_		_		_		_		_		_		_
Non-operating expenses		1.7		2.5		2.7		1.2		1.9		5.7		2.5		5.0		5.1
Other income/expense		_		(0.1)		(0.3)		0.1		0.1		_		0.2		(0.1)		_
Adjusted EBITDA	\$	(14.1)	\$	(14.3)	\$	(12.4)		\$ (13.2)	\$	(12.3)	\$	(12.0)	\$	(9.8)	\$	(12.6)	\$	(11.6)
Income from operations margin		n.a		n.a		n.a		n.a		n.a		n.a		n.a		n.a		n.a
Adjusted EBITDA margin		n.a.		n.a.		n.a.		n.a.		n.a.		n.a.		n.a.		n.a.		n.a.

Consolidated

_									Suc	cessor								
(\$ in millions)	Q1	2024	Q4	2023	Q3	2023	Q2	2023	Q1	2023	Q4 2	2022	Q3	2022	Q2	2022	Q1	2022
Revenue	\$	192.6	\$	230.4	\$	191.2	\$	197.2	\$	182.1	\$	217.9	\$	160.9	\$	175.8	\$	163.2
YoY % Growth - Total		5.8 %		5.7 %		18.8 %		12.2 %		11.6 %		20.5 %		8.7 %		(4.3)%		(4.3)%
YoY % Growth - Organic		5.5 %		5.3 %		17.3 %		8.4 %		7.9 %		19.1 %		9.0 %		(1.7)%		(4.2)%
YoY % Growth - Acquisitions		— %		(1.1)%		(1.0)%		3.1 %		5.7 %		6.4 %		5.4 %		1.8 %		2.5 %
YoY % Growth - FX		0.3 %		1.5 %		2.5 %		0.7 %		(2.0)%		(5.0)%		(5.7)%		(4.4)%		(2.6)%
Income (Loss) from Operations	\$	(4.9)	\$	13.4	\$	(11.1)	\$	(10.6)	\$	(13.6)	\$	(161.9)	\$	(27.6)	\$	(74.6)	\$	(33.6)
Amortization		31.5		31.8		32.7		33.2		33.6		34.3		35.2		37.5		38.8
Depreciation - core		5.7		6.6		6.3		6.0		6.2		6.3		5.8		5.6		4.6
Depreciation - Mirion Business Combination step-up		1.6		1.6		1.6		1.6		1.6		1.5		1.6		1.7		1.6
Stock compensation		3.6		4.2		6.1		6.0		5.6		7.0		8.5		8.5		7.8
Cost of revenue impact from purchase accounting		_		_		_		_		_		_		_		_		6.3
Goodwill impairment		_		_		_		_		_		156.6		_		55.2		_
Non-operating expenses		2.1		3.4		3.6		8.1		3.1		13.0		7.1		8.4		9.4
Other income/expense		(0.1)		_		(0.4)		_		0.1		(0.4)		0.2		0.3		_
Adjusted EBITDA	\$	39.5	\$	61.0	\$	38.8	\$	44.3	\$	36.6	\$	56.4	\$	30.8	\$	42.6	\$	34.9
Income from operations as a % of Revenue		(2.5)%		5.8 %		(5.8)%		(5.4)%		(7.5)%		(74.3)%		(17.2)%		(42.4)%		(20.6)%
Adjusted EBITDA as a % of Revenue		20.5 %		26.5 %		20.3 %		22.5 %		20.1 %		25.9 %		19.1 %		24.2 %		21.4 %

Consolidated – Income from Operations, Gross Profit & Adjusted EBITDA

(\$ in millions)	 lonths Ended h 31, 2024	Three Months Ended March 31, 2023				
GAAP Net Loss	\$ (26.5)	\$	(42.9)			
Interest expense, net	13.8		14.9			
Income tax expense (benefit) provision	1.2		(1.1)			
Foreign currency (gain) loss, net	0.8		(0.3)			
Change in fair value of warrant liabilities	5.7		13.4			
Debt extinguishment	_		2.6			
Non-operating expenses	_		(0.1)			
Other income/expense	0.1		(0.1)			
Income (Loss) from Operations	\$ (4.9)	\$	(13.6)			
Amortization	\$ 31.5	\$	33.6			
Depreciation	7.3		7.8			
Stock compensation expense	3.6		5.6			
Non-operating expenses	2.1		3.1			
Other income/expense	(0.1)		0.1			
Adjusted EBITDA	\$ 39.5	\$	36.6			
Gross Profit	\$ 87.1	\$	79.1			
Amortization	6.8		6.8			
Depreciation	5.3		4.9			
Revenue adjustment from purchase accounting	_		-			
Non-operating expenses	_		0.3			
Adjusted Gross Profit	\$ 99.2	\$	91.1			
Adjusted Gross Profit margin	51.5 %		50.0 %			

24

Adjusted Earnings per Share

(\$ in millions)	 Months Ended ch 31, 2024	 nths Ended 31, 2023
Net loss attributable to Mirion Technologies, Inc. / Mirion Technologies		
(TopCo), Ltd. stockholders	\$ (25.8)	\$ (41.9)
Loss attributable to noncontrolling interests	(0.7)	(1.0)
GAAP Net Loss	(26.5)	(42.9)
Foreign currency (gain) loss, net	0.8	(0.3)
Amortization of acquired intangibles	31.5	33.6
Stock based compensation	3.6	5.6
Change in fair value of warrant liabilities	5.7	13.4
Debt extinguishment	_	2.6
Non-operating expenses	2.1	3.0
Tax impact of adjustments above	(4.5)	(4.4)
Adjusted Net Income	\$ 12.7	\$ 10.6
Weighted average common shares outstanding — basic and diluted	199.729	187.701
Dilutive Potential Common Shares - RSU's	0.758	0.248
Adjusted weighted average common shares — diluted	200.487	187.949
Net loss per common share attributable to Mirion Technologies, Inc.	\$ (0.13)	\$ (0.22)
Adjusted EPS	\$ 0.06	\$ 0.06

Adjusted Order Growth (Decline)

		а		b	a - b = c	c / b = d
	Three	Months Ended	Т	hree Months Ended		
(\$ in millions)	Mar	ch 31, 2024		March 31, 2023	 Variance (\$)	Variance (%)
Total Orders	\$	182.0	\$	184.0	\$ (2.0)	-1.1%
Adjustment for ec ² Acquisition		(3.1)		-		
Adjustment for Biodex Divestiture		-		(2.5)		
Adjusted Orders	\$	178.9	\$	181.5	\$ (2.6)	-1.4%

Leverage, Liquidity and Adjusted Free Cash Flow

(\$ millions)	1Q23	1Q24
Net cash provided by operating activities	\$(2.7)	\$6.0
Purchases of PPE and badges	(7.5)	(12.8)
Proceeds from derivative contracts	0	1.2
Cash used for non-operating expenses	3.0	1.1
Adjusted free cash flow	\$(7.2)	\$(4.5)
Ending cash balance	\$88	\$120
Debt from first lien term loan	697	695
Net Debt	\$609	\$575
LTM Adjusted EBITDA	166	184
LTM Adjusted EBITDA Contribution from M&A ¹	2	3
LTM Adjusted EBITDA Plus M&A Contribution	\$168	\$187
Total net debt / M&A Adjusted EBITDA (Net Leverage)	3.6x	3.1x

1) Reflects Adjusted EBITDA contribution from ec² if ec² had been acquired before the start of the LTM period.

27 References to 1Q23 and 1Q24 are to the three months ended March 31, 2023 and 2024, respectively.